Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, reviews the role of FLT3 inhibitors for treating patients with FLT3-mutated acute myeloid leukemia. Dr Perl discusses how FLT3 inhibitors should be incorporated into treatment regimens for patients receiving lower-intensity therapy.
Eunice Wang, MD, chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, discusses the outlook of acute myeloid leukemia (AML) treatment in the wake of…
Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, presents promising…
Rajneesh Nath, MD, medical oncologist at the Banner MD Anderson Cancer Center, discusses early results from the phase 3 SIERRA trial investigating the efficacy of Iomab-B and protocol-specified…
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
Courtney D. DiNardo, MD, clinical researcher in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses how potential doublet…
Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet…
Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his…
Phase 3 ASCERTAIN Trial Shows Promising Results with Oral Decitabine and Cedazuridine Combination for the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses the significant advancements…
